Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BRYAN BURT and HEE-JIN JANG.
BRYAN BURT
Connection Strength
3.617
HEE-JIN JANG
  1. Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. Clin Cancer Res. 2025 Jul 01; 31(13):2639-2654.
    View in: PubMed
    Score: 0.977
  2. Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. Cancer Res. 2022 07 18; 82(14):2593-2609.
    View in: PubMed
    Score: 0.796
  3. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
    View in: PubMed
    Score: 0.207
  4. Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Ann Thorac Surg. 2022 11; 114(5):1842-1852.
    View in: PubMed
    Score: 0.188
  5. Improvement of Disability in Neurogenic Thoracic Outlet Syndrome by Robotic First Rib Resection. Ann Thorac Surg. 2022 09; 114(3):919-925.
    View in: PubMed
    Score: 0.187
  6. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma. Ann Thorac Surg. 2021 11; 112(5):1575-1583.
    View in: PubMed
    Score: 0.178
  7. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. J Thorac Cardiovasc Surg. 2020 04; 159(4):1598-1610.e3.
    View in: PubMed
    Score: 0.165
  8. Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation?. Interact Cardiovasc Thorac Surg. 2019 03 01; 28(3):353-359.
    View in: PubMed
    Score: 0.157
  9. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
    View in: PubMed
    Score: 0.148
  10. Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features. Clin Cancer Res. 2017 Aug 15; 23(16):4855-4864.
    View in: PubMed
    Score: 0.138
  11. Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. Gut. 2017 02; 66(2):215-225.
    View in: PubMed
    Score: 0.132
  12. Exposure-inducible genes may contribute to missingness in RNAseq-based gene expression analyses. Sci Rep. 2025 Aug 22; 15(1):30889.
    View in: PubMed
    Score: 0.062
  13. Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes. BMC Cancer. 2025 Jul 14; 25(1):1169.
    View in: PubMed
    Score: 0.061
  14. Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. J Thorac Cardiovasc Surg. 2025 Apr; 169(4):1082-1095.e4.
    View in: PubMed
    Score: 0.058
  15. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024 Jul 08; 42(7):1202-1216.e8.
    View in: PubMed
    Score: 0.057
  16. Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma. NPJ Precis Oncol. 2024 Feb 23; 8(1):47.
    View in: PubMed
    Score: 0.056
  17. Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res. 2022 12 01; 28(23):5121-5135.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.